eubiologics

Á¦Ç° ¹× ¿¬±¸°³¹ß

Development and supply of safe and effective vaccine for global public health

¿î¹Ý´Ü¹éÁú

rCRM197

rCRM197Àº À¯ÀüÀÚ ÀçÁ¶ÇÕ ´ëÀå±Õ(ƯÇã¹øÈ£ 10-2099342)À¸·ÎºÎÅÍ »ý»êµÇ´Â ´Ü¹éÁú·Î õ¿¬Çü(µðÇÁÅ׸®¾Æµ¶¼Ò) CRM197°ú µ¿ÀÏÇÑ È¿´ÉÀÇ Á¦Ç°ÀÔ´Ï´Ù. ´Ù¼öÀÇ Ç׿øµéÀº ´Ü¹éÁú¿¡ È­ÇÐÀûÀ¸·Î ¿¬°áµÇÁö ¾Ê´Â ÇÑ, ƯÈ÷ ¿µÀ¯¾Æ¿¡¼­ ¸é¿ª¿ø¼ºÀÌ ³·¾Æ, Á¢ÇÕ¹é½ÅÀ¸·Î Á¦Á¶µË´Ï´Ù. ÀÌ·¯ÇÑ Á¢ÇÕ¹é½Å¿¡¼­ ´Ü¹éÁú ¼ººÐÀ» ¡°¿î¹Ý´Ü¹éÁú(Carrier Protein)¡±À̶ó°íµµ ÇÕ´Ï´Ù.
CRM197Àº ´Ü¹éÁú-´Ù´ç·ù Á¢ÇÕ¿¡¼­ ¿î¹Ý ´Ü¹éÁú·Î ÈçÈ÷ »ç¿ëµÇ¸ç, ƯÈ÷ ´Ù¸¥ ¿î¹Ý´Ü¹éÁúÀÎ µðÇÁÅ׸®¾Æ Åå¼ÒÀ̵å, Å׳ª´©½º Åå¼ÒÀÌµå ´Ü¹éÁúÀ» ´É°¡ÇÏ´Â ¿©·¯ ÀåÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ´ç»çÀÇ rCRM197Àº À¯ÀüÀÚÀçÁ¶ÇÕ ´ëÀå±ÕÀ» ÀÌ¿ëÇÏ¿© ´ë·®»ý»êÀÌ °¡´ÉÇÏ°í, ¼öÀ²ÀÌ ³ôÀº ÀåÁ¡À» °¡Á® ÀåƼǪ½º Á¢ÇÕ¹é½Å(TCV:Typhoid Conjugate Vaccine), ¼ö¸·±¸±ÕÁ¢ÇÕ¹é½Å(MCV:Meningococcal Conjugate Vaccine), Æó·Å±¸±ÕÁ¢ÇÕ¹é½Å(PCV:Pneumococcal Conjugate Vaccine) °³¹ß¿¡ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù.
Á¦Ç°¸í rCRM197
Á¦Ç°±¸ºÐ ¿¬±¸¿ë ½Ã·á, GMP grade(¹é½Å °³¹ß¿ë)
¿ëµµ ¸é¿ªÁõ°­¿ë Àü´Þ ´Ü¹éÁú
°¡°Ý \260,000/mg
ƯÇã ÀçÁ¶ÇÕ ´ëÀå±ÕÀ» ÀÌ¿ëÇÑ rCrm197 »ý»ê¹æ¹ý(ƯÇã¹øÈ£ : 10-2048456)
CRM197 ´Ü¹éÁú ¹ßÇö ¹æ¹ý(ƯÇã¹øÈ£ : 10-2142255)
³í¹® 1)Production of Carrier Protein rCRM197 Using Recombinant E.coli
(https://www.e-ksbbj.or.kr/journal/view.html?uid=145&vmd=Full)
2)An open-label, comparative, single dose, clinical Phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults
(https://www.sciencedirect.com/science/article/abs/pii/S0264410X21004059?via%3Dihub)
3)Generation of a human monoclonal antibody to cross-reactive material 197 (CRM197) and development of a sandwich ELISA for CRM197 conjugate vaccines
(https://www.jmb.or.kr/journal/view.html?doi=10.4014/jmb.1810.10009)
Immune-Enhancing Carrier protein, rCRM197

Á¦Ç°¼ººÐ

Source
Escherichia coli

Á¦Ç°Á¤º¸

Æ÷Àå´ÜÀ§ ÀúÀå¹æ¹ý À¯È¿±â°£ ¼øµµ
0.5 mg/vial, 1.0 mg/vial
°í°´¸ÂÃãÇü Á¦ÀÛ°¡´É
2 ~ 8¡É Á¦Á¶ÀϷκÎÅÍ 12°³¿ù 95% ÀÌ»ó


Á¦Ç° ±¸¸Å °ü·Ã ¹®ÀÇ»çÇ×Àº sales@eubiologics.comÀ¸·Î ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù.